复星医药：关于控股子公司药品获美国FDA孤儿药资格认定的提示性公告

Core Viewpoint - Fosun Pharma's subsidiary, Shanghai Fuhong Hanlin Biotechnology Co., Ltd., has received Orphan-drug Designation from the FDA for its investigational drug HLX43, a PD-L1 targeted antibody-drug conjugate for the treatment of thymic epithelial tumors (TETs) [1] Group 1 - The investigational drug HLX43 is specifically designed for the treatment of thymic epithelial tumors [1] - The FDA's Orphan-drug Designation is a significant milestone for the company, potentially facilitating the drug's development and commercialization [1]